AgomAb Therapeutics NV, a clinical‑stage biotech backed by EQT Life Sciences, debuted on the exchange Friday at 8.1% below its $200 million IPO price. The Dutch‑registered firm raised the full target amount, but early trading saw shares slip, signaling cautious investor sentiment toward new‑stage biopharma listings amid broader market volatility and heightened scrutiny of valuation models.

Investors had hoped the EQT Life Sciences partnership would lend credibility, given the private equity firm's track record of scaling niche drug developers. Yet recent IPOs in the sector have struggled to sustain pricing, as analysts flag uncertain reimbursement pathways and the need for late‑stage trial data to justify premium valuations.

Market watchers will monitor AgomAb’s upcoming Phase II readouts for its lead antibody platform, which could determine whether the $200 million capital raise translates into meaningful clinical milestones. A rebound in share price would reassure backers, while continued weakness may prompt a reassessment of EQT’s exposure to early‑stage biotech ventures.